U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056803) titled 'Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus' on June 29.
Brief Summary: This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a specific focus on sex-based differences in metabolic response. A total of 212 patients were enrolled and evenly assigned to either oral or subcutaneous semaglutide. The primary outcome was the change in HbA1c, while secondary outcomes included variations in weight, lipid profile, liver function, and hepatic steatosis index. Subcutaneous semaglutide resulted in great...